Biocon Limited launches Liraglutide in the Netherlands
Biocon Limited an innovation-led global biopharmaceutical company, announced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza®) and obesity (gSaxenda®), in the Netherlands through its distribution partner Pharmamedic B.V.




















